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M
anagement of tricuspid regurgitation (TR) is becoming an increasingly difficult decision-
making problem. TR occurs in 8–35% of patients, especially in association with acquired left
heart valve disease of rheumatic origin, primary isolated TR being very rare. It is more
frequently found in association with mitral rather than with aortic valve disease, and is much rarer in
degenerative disease. In the majority of patients (70–85%), the TR is said to be ‘‘functional’’, caused
by dilatation of the annulus as a result of increased pulmonary and right ventricular pressure; in the
remaining 15–30% of the cases it may be organic and related to direct involvement of the tricuspid
valve by the rheumatic disease.1 2 Whichever type, TR has a significant impact on the clinical
condition and the medium and long-term prognosis of the patients. Hence, it requires special
consideration during mitral and/or aortic valve surgery and thereafter.
In 1967, Brawnwald et al3 advised a conservative (no touch) approach to TR. Indeed, it was thought
that appropriate correction of the left-sided valve disease would most probably result in a decrease or
even abolition of the so-called functional TR. However, experience has shown that TR does not
always disappear, and may increase, especially when the mitral and/or aortic valve disease is not
completely or adequately resolved during surgery, as happens sometimes in cases with less than
perfect correction of mitral regurgitation or stenosis. Furthermore, isolated severe TR is now
increasingly observed in patients with normal left heart valve function after either mitral valve
annuloplasty or replacement. The true incidence of secondary TR is not well known, but it has led
some to question the functional nature of TR, accompanying left-sided valve disease.
Even moderate TR observed during surgery of left heart valves may not regress spontaneously,
especially when there is already a degree of right ventricular dysfunction indicated by annular
dilatation. In their experience with patients who were subjected to valvuloplasty for mitral valve
regurgitation, Dreyfus et al4 found that the tricuspid annulus was abnormally dilated in about 50% of
the patients, even in the absence of TR.
PHYSIOPATHOLOGYc
For more than 25 years, we have been aware of tricuspid annular dilatation and indeed significant TR
in a large number of rheumatic patients subjected to mitral valve surgery.5–7 We have shown that the
initial and principal pathological process affecting the mitral valve in acute rheumatic carditis is
dilatation of the annulus. In other words, the mitral annulus is abnormally weak due to rheumatic
involvement.6 8–11 It is therefore not surprising that the tricuspid annulus is similarly affected in some
instances.
Others have demonstrated that loss of contraction of the myocardium surrounding the annulus is
the leading mechanism of TR.12 We learnt, in fact, that so-called ‘‘functional’’ TR occurs in rheumatic
heart disease only where there is severe pulmonary hypertension and the amount of regurgitation is
relatively small.3 10 ‘‘Functional’’ is a misleading term when used in the context of tricuspid valve
disease. As with the mitral valve, annular pathology plays as important a role in causing valve
malfunction as do leaflet, chordal or papillary muscle disease. Haemodynamically significant TR
before rheumatic mitral valve surgery should not be regarded as functional, nor should it be
anticipated that the TR will resolve after successful mitral surgery. Immediately after such surgery,
the TR may appear relatively mild and easily controlled with diuretics. After months or years,
however, forceful systolic waves and a pulsatile liver supervene.6 13
TR is often a progressive condition. With the increased volume of TR, the right ventricle, as well as
of course the right atrium, dilate. Eventually the right ventricular systolic function ‘‘fails’’, the
diastolic pressure rises and the interventricular septum moves towards the left ventricle during
diastole. This is an important example of cardiac chamber inter-relationships in which elevated
pressure and expanding volume of one chamber compress, or constrain, the adjacent chamber and
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hence raises the pressure in the latter. These interrelated
ventricular cavity pressure and volume alterations are essential
features of the ‘‘restriction-dilatation syndrome’’.6 13 14 We
named it restriction-dilatation syndrome because decreased
left ventricular cavity size, aggravated sometimes by fibrous
adhesions following previous surgery, especially left thoracot-
omy, has raised left ventricular diastolic pressures and results
in a rise in pulmonary venous pressure. Naturally, this
perpetuates and increases the TR. It is the essential feature
predisposing to and later aggravating the restriction-dilatation
syndrome. Tricuspid valve surgery carries a high surgical
mortality when performed in the context of the restriction-
dilatation syndrome with severe TR. An aggressive approach to
the tricuspid valve at the time of rheumatic mitral valve surgery
has, for practical purposes, prevented this previously prevalent
postoperative complication in our institutions.
Right ventricular dysfunction and TR are more common in
mitral than in aortic valve disease. Lowering of pulmonary
vascular resistance, generally increased in mitral valve disease,
is essential for reversal of TR. A longer clinical course could
result in a greater degree of clinical and haemodynamic
deterioration, thus with increased surgical risk. In the presence
of right ventricular failure, operative mortality increases from
5% to 11% and from 8% to 22% during follow-up.15 On the other
hand, improvement of symptoms is less common in valvular
patients with preoperative right ventricular dysfunction (ejec-
tion fraction ,30%).16 Finally, persisting TR following mitral
valve replacement is associated with an impaired cardiac output
response to exercise.17 Hence, recent evidence demonstrates
that functional TR can be ignored only in patients with
predictable and significant reduction in the pulmonary resis-
tance, which usually follows earlier correction of left-side
pathology.
INDICATIONS FOR SURGERY OF THE TRICUSPID
VALVE
When should one repair/replace the tricuspid valve in associa-
tion with surgery of left-sided heart valve disease?
There are a certain number of problems that complicate the
decision. Firstly, there is no reliable method to judge how much
of the TR is reversible when the left heart valve dysfunction is
corrected. Secondly, there is a lack of reliable and repeatable
methods of measuring and quantifying the degree of TR; it is
certainly more difficult than with the mitral valve and one
cannot rely on echocardiography alone. The clinical assessment
is extremely important here. Finally, there is no satisfactory
method to assess true right ventricular function.
Some other questions remain unanswered. What is the
choice between repair and replacement? What is the effective-
ness of different methods of repair? What type of prosthesis is
to be used if the valve is replaced? What can be done with mild
to moderate tricuspid incompetence? Finally, how do you
predict those patients who will return after mitral valve surgery
with persistent, sometimes very bothersome, TR?
In their recent paper, Dreyfus et al4 dealt with the problem of
secondary tricuspid dilatation, with or without regurgitation
(should it be corrected?). These authors reviewed their
experience with patients who were subjected to valvuloplasty
for mitral valve regurgitation and observed echocardiographi-
cally, in about 50% of their total series, that the tricuspid
annulus was abnormally dilated although TR was seldom
demonstrated. Two groups of patients were compared retro-
spectively: in one group, patients had a simultaneous tricuspid
annuloplasty, while in the other group the tricuspid valve was
left undisturbed. The authors found that in the late follow-up,
the patients who had tricuspid annuloplasty had a progressive
decrease in the degree of regurgitation, while patients who did
not have a tricuspid annuloplasty had progressive tricuspid
dysfunction.
Consequently, they proposed that tricuspid annuloplasty be
done at the time of mitral valve surgery when the diameter of
the annulus is greater than 21 mm/m2, and this was found to
improve functional capacity without increasing perioperative
morbidity and/or mortality. Basically, what these authors are
proposing is ‘‘prophylactic’’ annuloplasty in order to avoid
progression of the disease. Their numbers are convincing but
require validation by other authors’ experiences. But in recent
years we have been increasingly aggressive to the tricuspid
valve. Annuloplasty adds only a very short time to cardiopul-
monary bypass and aortic crossclamping (it can even be done
after release of the aortic crossclamp) and, at least in our
experience, does not seem to add significantly to perioperative
mortality and morbidity (see below).
This problem is especially pertinent in patients with mitral
stenosis. Wong et al18 and other authors have also dealt with
this subject and recommended that annuloplasty be performed
at least in TR grades II and III. Also from the international
guidelines, there is some evidence that annuloplasty should be
performed for more than mild TR, especially in patients with
pulmonary hypertension secondary to mitral valve disease
requiring surgery.
LATE OCCURRING TRICUSPID REGURGITATION
Late appearance of TR requiring reoperation is exemplified by a
patient who has been subjected to mitral surgery and presents
weeks, months or years later with symptoms and signs of right
and/or left heart failure, and significant TR. In the past 20 years,
we have had to proceed to reoperation for isolated tricuspid
valve annuloplasty in many patients previously subjected to
surgery of left heart valve disease. This procedure is associated
with a significant surgical risk.
What are the risk factors for persisting or worsening TR after
a mitral valve procedure without surgery to the tricuspid valve?
First is the mechanism, discussed above, of persisting or
recurrent mitral valve disease which predisposes to tricuspid
dysfunction. On the other hand, the more severe the TR already
present at the time of the first surgery, the more likely it is to
persist or to increase late after mitral valve surgery. Mild TR
rarely persists or progresses, whereas moderate or severe TR
Factors in the genesis of the restrictive-dilatation
syndrome
c Mitral valve dysfunction
c Myocardial dysfunction or other reason for left ventricular
dilatation
c Pulmonary thromboembolic disease and chronic obstructive
airways disease
c Functional or organic tricuspid regurgitation
c Pericardial restriction or constriction
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may and usually does so. Finally, longstanding, perhaps
irreversible, right ventricular dilatation secondary to mitral
valve or pulmonary vascular disease probably also predisposes
to persistent TR. All these factors take part in the restriction-
dilatation syndrome described above.
Therefore, TR that does not disappear immediately after
surgery with intensive pre- and postoperative anti-congestive
therapy is more likely to persist postoperatively if not repaired.
On the other hand, organic TR, usually associated with some
degree of stenosis, is more likely to persist than is ‘‘functional’’
TR.
Late TR appears to be preferentially associated with rheu-
matic heart disease. In a recent study of 264 patients who had
mitral valve repair at Papworth Hospital, Cambridge, where just
over 80% had had degenerative mitral regurgitation, significant
TR was not detected clinically 1–11 years after mitral valve
repair.19 It must be recognised, however, that specific clinical
observations on the tricuspid valve were not a principal goal of
the study and that diuretic treatment may have masked
moderate TR in some instances. On the other hand,
Matsunaga and Duran20 found that functional TR is frequently
associated with functional ischaemic mitral regurgitation. In
their experience, close to 50% of patients have TR after mitral
valve repair and the incidence of postoperative TR increased
with time. They hypothesised that preoperative tricuspid
annulus dilation might be a predictor of late TR.
It certainly would be contributory to thousands of patients
with rheumatic heart disease if surgeons and cardiologists
would refute the prolonged and ongoing dogma that ‘‘func-
tional’’ TR will subside after appropriate left-sided rheumatic
valve surgery and that they practise an aggressive policy
towards performing, even prophylactically, tricuspid annulo-
plasty at the time of such surgery. Nonetheless, based on
currently available data, an indication for tricuspid annulo-
plasty at the time of mitral surgery for degenerative disease can
barely be substantiated.
So, what are the surgical considerations when dealing with
the problem of late tricuspid valve regurgitation?
In these cases, there are two situations to consider: is this a
first tricuspid valve procedure—that is, originally the patient
had only mitral or aortic valve surgery—or was there an
intervention on the tricuspid valve already during the first
procedure, in which case it is a repeat tricuspid valve operation?
In either case, the patient may also present with another valve
disease, or otherwise it may be an isolated problem of TR, a
problem which we see with increasing frequency.
It is quite clear that redo heart surgery of any sort is
associated with a higher risk, which is magnified by the
number of times it takes place. Hospital mortality for repeat
tricuspid valve surgery in patients who had a prior cardiac
operation may reach 50%, although it is usually described
between 10–20%.21 Surgery in patients with isolated organic TR
should, therefore, be delayed unless there is a good reason to
believe that a successful valvuloplasty can be performed or the
patient continues to show signs of cardiac failure despite
adequate diuretic treatment. Aggressive anti-failure therapy is
indicated and should be maximised to the limits of patient
tolerance. We further believe that long-term, perhaps indefi-
nite, anti-failure therapy may avoid or at least retard the
development of significant TR.
High functional class, severe right heart failure, low right
ventricular ejection fraction, high pulmonary pressure and
pulmonary arterial resistance are additional risk factors when
repeating tricuspid surgery. As mentioned, large right
ventricular volumes specifically affect the risk for re-entry
sternotomy, but this may be obviated by adequate surgical
technique, as discussed below.
FOLLOW-UP AND DIAGNOSIS
Patients who have undergone mitral valve surgery are routinely
subjected to close follow-up. Patients who have had tricuspid
valve surgery or have TR which was not completely resolved
after left-sided valve surgery require no special considerations,
but should be followed more closely.
Clinical detection of TR is simple and accurate.6 13 Raised
jugular venous pressure, hepatomegaly, pulsatile liver and
hepato-jugular reflux are followed by ankle swelling and, later,
by ascites and generalised oedema. The characteristic systolic
wave is both visible and palpable in the neck veins. On
auscultation, a systolic murmur, variable with respiration, is
usually present. Echocardiographic examination confirms the
diagnosis and is useful to assess the size of the right cardiac
chambers and right ventricular function. In severe TR there is
usually dilatation of both the right atrium and ventricle.
Retrograde flow in the vena cava is synonymous with severe TR.
TR is probably partially related to the enlargement of the
right-sided heart cavities and to alterations in the geometry of
the right ventricle, and a decrease in the volaemia may help to
obviate the problem. We must emphasise that TR is not benign.
It is often self-perpetuating, progressive and becomes very
incapacitating to the patient who has to receive massive doses
of diuretics or be subjected to high-risk surgery.
Once the patient becomes symptomatic, aggressive anti-
failure therapy with furosemide is indicated—usual doses are
40–160 mg daily. Spironolactone appears especially indicated in
patients with TR and in right ventricular failure. Dosages of 25–
100 mg daily may be utilised, depending on the clinical
situation and on the response. We are well aware that diuretic
treatment may reduce the haemodynamic severity of TR by
relieving right ventricular distension and hence lowering right
atrial pressure. If this is not sufficient, consideration must be
given to isolated surgery of the tricuspid valve.
A B
Figure 1 Classical DeVega annuloplasty.
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SURGICAL TECHNIQUE
In the tricuspid position, prosthetic valve substitutes have at
least the same type and degree of complications as in the aortic
and the mitral positions. Mechanical prostheses have an
increased incidence of thrombo-embolic phenomena, while
bioprostheses have the problem of early and late degeneration,
depending on the age of the patient. The use of mechanical
prostheses in the tricuspid position in multi-valvular proce-
dures has been associated not only with increased mortality but
also with a high incidence of thrombotic complications, valve
dysfunction from tissue ingrowth and, in the case of cage and
ball valves, incorporation of the cage into the wall of the right
ventricle. Although thrombolytic treatment has, in recent years,
been successfully applied in the treatment of thrombosis of
tricuspid mechanical prostheses, it remains a very serious and
often lethal problem. Survival curves show that by five years
only about 35–45% of the patients were alive free from
reoperation after tricuspid valve replacement.22
On the other hand, partial or total replacement of the
tricuspid valve with homografts has been suggested and has
been done quite extensively by some groups, but the results are
still not homogeneous and, in some cases, controversial.
But it appears that only exceptionally does the tricuspid valve
need to be replaced as a first procedure, because the valve
tolerates well a less than perfect repair, in contrast to what
happens with the aortic and the mitral valves where total
competence is of primordial importance. Hence, in the minds of
almost everybody, annuloplasty is the surgery of choice when
dealing with most forms of TR.
In the early 1970s, Deloche et al,23 from Carpentier’s group,
clearly demonstrated that dilatation of the tricuspid annulus
occurs almost entirely in the mural portion of the annulus;
based also on his own findings, DeVega24 developed his very
well known procedure, which consists of plication of the
posterior and anterior portion of the annulus, preserving the
septal portion, with a double continuous suture (fig 1). This
procedure has since been used in tens of thousands of cases by
most surgeons throughout the world and it appears to be safe
and efficacious. Sometimes, however, the sutures may pull out
of the tissues and the guitar-string syndrome occurs. In order to
avoid this type of complication, in 1987 Antunes and
Girdwood25 described a modification of the procedure which
consisted of the interposition of Teflon pledgets in each bite of
the suture, but the concept remains exactly the same (fig 2).26
Other methods of suture-annuloplasty have been described and
used by some groups, but the DeVega annuloplasty or its
modifications has gained wider acceptance. In these situations,
the valve is usually made mildly stenotic, but it has been
emphasised that tricuspid stenosis is a relatively benign lesion,
usually well tolerated by the patient.6 13
The routine use of an annuloplasty ring, whether pre-shaped,
rigid or semi-rigid, as the Carpentier ring, or flexible, as the
Duran ring, has been considered superior and recommended by
many groups.27 However, in our experience, the implantation of
a ring is specifically indicated when there is organic involve-
ment of the tricuspid valve, usually with stenosis, where
commissurotomy is also necessary. In these circumstances,
because remodelling of the annulus is probably essential, we
prefer the Carpentier ring (fig 3). In all other cases, we use the
modified DeVega annuloplasty.28
Somewhat different is the problem of late appearing TR. In
most repeat operations, morbidity and even mortality is often
related to the re-entry. Classical median sternotomy may be
used, but a right thoracotomy may be advantageous for a
second and third reoperation. On the other hand, the adhesions
of the pericardium, together with extreme dilatation of the
right atrium and ventricle, may dictate the need for using
peripheral artery (for example, femoral) and even vein
cannulation in some cases, especially in multiple reoperations,
although we have not had to utilise it frequently. We still use
the median sternotomy and the classical vena cavae–aortic
cardiopulmonary bypass in the vast majority of cases.
If it had not been done previously, annuloplasty is, again,
preferable to valve replacement. In these cases, however,
A B C Figure 2 Authors’ modification of the
DeVega annuloplasty.
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greater tendency for deformity of the whole valve mechanism,
rather than isolated annular dilatation, may dictate more
extended use of a prosthetic ring.
SURGICAL RESULTS
In our experience, the modified DeVega tricuspid annuloplasty
proved to be a safe and efficacious procedure for the manage-
ment of secondary TR. It is technically easy and reproducible,
even by relatively inexperienced surgeons. In our view, it
should be used in all patients with more than mild ‘‘functional’’
TR. We26 28 have recommended and followed this policy for
more than a decade with encouraging results, inasmuch as we
have observed a low rate of late reoperations.
Beginning March 1988 through December 2004, 495 patients
were subjected to surgery of the tricuspid valve, together with
surgery of the mitral valve, in our department in Coimbra,
Portugal. Only five patients required valve replacement. Of the
remainder, 48 (9.7%) had implantation of a Carpentier ring and
442 had the modified DeVega procedure. The 30-day mortality
for patients who had tricuspid annuloplasty was 1.6% as
compared with 1.0% in those without tricuspid valve surgery.
To our knowledge, only three patients required reoperation for
persistent or recurrence of severe TR and no case of dehiscence
of the annuloplasty suture was identified.
We believe that the modified technique, almost abolishing
suture dehiscence, may have contributed significantly toward
the difference between our experience and that recently
reported by McCarthy and co-authors.27
On the other hand, reoperation for late TR, whether isolated
or in conjunction with repeat surgery of another valve, has an
operative risk which is higher than that which occurs after
other redo valve surgery and may reach 10–20%, although
much lower mortality rates have recently been reported.29 30
Preoperative preparation to reduce cardiac failure, and phy-
siotherapy, adequate anaesthesia and surgical technique may
contribute to reduce the risk. Special attention must be given to
renal function, as significant renal failure dramatically
increases the surgical risk. Because surgery is rarely required
on an emergency basis, all measures that may improve the
patient’s condition before surgery are justified.
CONCLUSION
It is obvious that functional TR can be ignored only in patients
with a predictable and significant reduction in pulmonary
resistance. The quality of the repair or replacement of the left-
sided valvulopathy appears fundamental to avoid late TR.
Secondary dilatation of the tricuspid annulus without regur-
gitation is present in a significant number of patients with
severe mitral regurgitation and is a progressive disease which
often does not resolve with correction of the primary lesion
alone. Tricuspid annuloplasty at the time of mitral valve surgery
improves functional capacity without significantly increasing
perioperative morbidity and mortality.
It is, thus, appropriate to recommend that surgeons be more
liberal in the indications for tricuspid annuloplasty. It should be
performed if the tricuspid insufficiency is more than mild and
one or more of the following factors are present: the valve is
rheumatic, the size of the annulus is .21 mm/m2, there is
dilatation of the right chambers and inferior vena cava, and
there is right ventricular overload. If TR occurs or progresses
late after valve surgery, aggressive medical treatment is
indicated but surgery of the tricuspid valve may be required.
Although it carries a higher operative risk, patients usually
show significant clinical improvement.
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Management of tricuspid valve regurgitation: key
points
c Tricuspid regurgitation (TR) is common in patients with left-
sided heart (especially mitral) valve disease
c There is now some evidence that, in these cases, TR is not
always ‘‘functional’’; it may be due to pathological
involvement of the annulus
c Therefore, correction of left-sided heart valve disease does
not automatically correct TR
c Dilatation of the tricuspid annulus is progressive and may
not be accompanied by TR initially, but eventually leads to it;
‘‘prophylactic intervention may be justified
c Tricuspid annuloplasty achieves excellent results; tricuspid
valve replacement is seldom necessary
c Suture annuloplasty is usually adequate but ring annulo-
plasty is essential in organic TR
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